Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Completed · Phase 4

Conditions studied: Neoplasms

In brief

Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator

Key facts

Study ID

NCT01789281

Run by

Novartis Pharmaceuticals

People needed

34

Starts

2013-05-14

Expected to finish

2020-08-28

Last updated by the study team

2021-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject enrolled in a Novartis-sponsored, CD\&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and fulfilled all their requirements in the parent study
• Subject benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol.

You may not qualify if…

• Subject was permanently discontinued from everolimus study treatment in the parent study.
• Subject was receiving everolimus in combination with an unapproved or experimental treatment
• Other protocol-defined inclusion/exclusion criteria might apply

Where it is running

• Hematology Oncology Services of Arkansas SC — Little Rock, Arkansas, United States
• Rocky Mountain Cancer Centers SC — Greenwood Village, Colorado, United States
• Stamford Hospital — Stamford, Connecticut, United States
• H Lee Moffitt Cancer Center and Research Institute SC-2 — Tampa, Florida, United States
• Central Indiana Cancer Centers SC — Indianapolis, Indiana, United States
• Crescent City Research Consortium, LLC SC-3 — Metairie, Louisiana, United States
• Mayo Clinic SC-2 — Rochester, Minnesota, United States
• Washington University School of Medicine Dept of Oncology — St Louis, Missouri, United States
• Nebraska Cancer Specialists Onc Dept — Omaha, Nebraska, United States
• Clinical Research Alliance — Lake Success, New York, United States
• New York University Medical Center SC-4 — New York, New York, United States
• Oregon Health and Science University SC-8 — Portland, Oregon, United States
• Utah Cancer Specialists Utah Cancer (2) — Salt Lake City, Utah, United States
• Novartis Investigative Site — Prague, Czech Republic, Czechia
• Novartis Investigative Site — Arezzo, AR, Italy
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Groningen, Netherlands
• Novartis Investigative Site — Leningrad Region, Russia, Russia
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Barcelona, Catalonia, Spain
• Novartis Investigative Site — Bangkok, Thailand
• Novartis Investigative Site — Izmir, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.